oligodendroglioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FoxG1 indices were similar in astrocytic and oligodendroglial tumours, whereas Olig-2 indices were increased in oligodendrogliomas compared to astrocytic tumours (n = 451, P < 0.0001).
|
29053887 |
2018 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig2 was positive in 5 out of 44 ependymomas (11%) and 50 out of 54 (93%) non-ependymal tumors (astrocytomas and oligodendrogliomas).
|
26287936 |
2016 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The means of Olig2 LI in glioma cells were 43.7 % in diffuse astrocytomas, 59.3 % in oligoastrocytomas and 76.1 % in oligodendrogliomas.
|
25085214 |
2014 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The oligodendroglioma areas showed immunoreactivity for Olig2 and mutant isocitrate dehydrogenase 1 protein, whereas the gangliocytoma and neurocytoma areas were positive for synaptophysin and NeuN.
|
24054724 |
2013 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig-2 stained 22 (91.6%) of 24 oligodendrogliomas and all dysembryoplastic neuroepithelial tumors but also 24 (80%) of 30 glioblastoma multiforme and 8 (80%) of 10 pilocytic astrocytomas.
|
21835431 |
2012 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A quantitative study showed that the Olig2-positive nuclei were much fewer in ependymomas than in astrocytomas and oligodendrogliomas.
|
18552083 |
2008 |
oligodendroglioma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In the current study, we found that overexpression of OLIG2 was not only found in oligodendroglioma samples and normal neural tissue but also in a wide spectrum of malignant cell lines including leukemia, non-small cell lung carcinoma, melanoma, and breast cancer cell lines.
|
16103065 |
2005 |
oligodendroglioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the current study, we found that overexpression of OLIG2 was not only found in oligodendroglioma samples and normal neural tissue but also in a wide spectrum of malignant cell lines including leukemia, non-small cell lung carcinoma, melanoma, and breast cancer cell lines.
|
16103065 |
2005 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, two bHLH transcription factors involved in oligodendroglial specification, Olig1 and Olig2 have been proposed as potential markers of oligodendrogliomas.
|
15164981 |
2004 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
LHGDN |
High OLIG expression alone has been proposed to distinguish oligodendrogliomas from astrocytomas, so we critically evaluated OLIG2 as a marker by immunohistochemical and oligonucleotide microarray analysis.
|
15198128 |
2004 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The oligodendrocyte lineage genes OLIG1 and OLIG2 have been reported as potential diagnostic markers for oligodendrogliomas [Lu et al.
|
14730454 |
2004 |
oligodendroglioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In situ hybridization showed that the OLIG2 gene was expressed by tumor cells in pilocytic astrocytomas as well as those in oligodendrogliomas.
|
12924709 |
2003 |
oligodendroglioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, combining Olig mRNA expression and immunohistochemistry of OLIG2 enables oligodendrogliomas to be distinguished from glioblastomas and other astrocytic glial tumors.
|
14575240 |
2003 |
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
OLIG2-positive cells corresponding to neoplastic oligodendrocytes were present in all oligodendrogliomas and oligoastrocytomas.
|
11498220 |
2001 |